Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.

Thyroid alterations are frequently associated with anti PD-1 treatment in cancer patients. Regular thyroid assessment should be performed, particularly in the first months of treatment and in patients with a pre-existing thyroid disease.